American Heart Month: Cardiovascular Care in Practice

Lowering blood glucose levels significantly reduces heart disease risks in prediabetes, offering new hope for prevention and management strategies.

In patients with ST-segment elevation myocardial infarction, lowering low-density lipoprotein cholesterol to optimal levels prevented neoatherosclerosis, a complication following stent implantation.

The novel agent has demonstrated efficacy in symptomatic and less severe patients with obstructive hypertrophic cardiomyopathy in thorough phase 3 clinical trials.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

Asundexian shows promise in reducing ischemic stroke risk without increasing major bleeding, offering hope for secondary stroke prevention.

Depression and cardiometabolic disease share hormonal, inflammatory, and behavioral pathways requiring integrated pharmacist-led recognition and management.

Biykem Bozkurt, MD, PhD, FACC, highlights the need for reliable activity monitoring in heart failure care, addressing challenges of digital wearables in clinical practice.

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Host Craig Beavers discusses the validity of meta-analyses and highlights analyses from European Society of Cardiology (ESC) 2025 with Bill Baker, PharmD, FCCP, FACC, FAHA.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Discover effective strategies for managing obesity to enhance cardiovascular health, including innovative treatments and the vital role of pharmacists.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.